BCL2A1 and glioblastoma: The results showed that compared with the control group, mRNA expressions of PN GBM markers including SOX2, NOTCH1, OLIG2, and CD133 in EGFRvIII (+) cells decreased, and MES GBM markers including CD44, BCL2A1, LYN, and WT1 were increased (p < 0.05) (Figure 3A–C).